Safety and efficacy of cerebral embolic protection devices during TAVI: a meta-analysis and sequence analysis of trials
- 1Universidade Federal do Piauí, Faculdade de Medicina Teresina PI Brazil
- 2Universidade Federal do Piauí, Faculdade de Medicina, Hospital Universitário Teresina PI Brazil
Abstract
Background: Cerebral embolic protection (CEP) devices have been developed to reduce postoperative neurological outcomes after transcatheter aortic valve implantation (TAVI); however, their effectiveness remains controversial.
Objective: To evaluate the impact of CEP use during TAVI on the occurrence in clinical outcomes.
Methods: Databases were used to search for randomized clinical trials. The occurrence of all strokes, of disabling strokes specifically, transient ischemic attacks (TIAs), all-cause mortality, and vascular complications were analyzed. Conventional meta-analysis was conducted using fixed-effects modeling and trial sequential analysis (TSA: type I error of 5%, power of 90%). The systematic review protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO; CRD420251081075).
Results: In total, eight clinical trials were included, gathering 11,589 patients randomized between those who used the devices (5,943) and those who did not (5,646). The meta-analysis demonstrated no significant association between CEP use and reduced odds of all-cause stroke (OR = 0.92, 95% CI: 0.73–1.15, p = 0.46) and disabling stroke (OR = 0.80, 95% CI: 0.57–1.13, p = 0.20). The sequential analysis identified a lack of evidence for all strokes (required sample size [rSS] = 38,626; 10.53%), disabling strokes (rSS = 59,732; 17.05%). In terms of mortality, there was no significance in the use of devices (OR = 1.09, 95% CI: 0.71–1.69, p = 0.69), reaching evidence for support (rSS = 7,053; 42.25%);
Conclusion: The data on the use of CEP is insufficient to support meta-analytic conclusions regarding cerebrovascular outcomes. Nevertheless, TSA demonstrated evidence supporting futility regarding mortality reduction.
Related
- Dual-guidewire technique with cerebral embolic protection for brachiocephalic trunk bifurcation stenosis: a case report
- Feasibility, safety, and efficacy of the amber peripheral liquid embolic system: results from stage I of the first-in-human OPAL study
- Evaluating Standard Shielding Versus Novel Enhanced Radiation Protection Devices in the Cardiac Catheterization Laboratory
- The protection of chronic cerebral ischemia by Hua-Feng-Dan involves the modulation of hippocampal transcriptome and gut dysbiosis
- Peptide Sequence Determines the Efficacy of Single-Dose AAV-Vectorized GLP-1R Agonists in Diet-Induced Obese Mice
BibTeX
@article{costa2026safety,
title = {{Safety and efficacy of cerebral embolic protection devices during TAVI: a meta-analysis and sequence analysis of trials}},
author = {Aldo José Silva de Castro Costa and Marcus Vinícius Costa Fernandes and Thaynar Cavalcante Batista and Ana Virgínia de Jesus Félix and Tamara Larissa Silva Barbosa and Isis Maria Lima Cruz and Gustavo Sousa Noleto},
journal = {Arquivos de Neuro-Psiquiatria},
year = {2026},
month = nov,
doi = {10.1055/s-0046-1829157},
url = {https://doi.org/10.1055/s-0046-1829157},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Safety and efficacy of cerebral embolic protection devices during TAVI: a meta-analysis and sequence analysis of trials
AU - Aldo José Silva de Castro Costa
AU - Marcus Vinícius Costa Fernandes
AU - Thaynar Cavalcante Batista
AU - Ana Virgínia de Jesus Félix
AU - Tamara Larissa Silva Barbosa
AU - Isis Maria Lima Cruz
AU - Gustavo Sousa Noleto
PY - 2026
DA - 2026/11/06
JO - Arquivos de Neuro-Psiquiatria
DO - 10.1055/s-0046-1829157
UR - https://doi.org/10.1055/s-0046-1829157
AB - Background: Cerebral embolic protection (CEP) devices have been developed to reduce postoperative neurological outcomes after transcatheter aortic valve implantation (TAVI); however, their effectiveness remains controversial. Objective: To evaluate the impact of CEP use during TAVI on the occurrence in clinical outcomes. Methods: Databases were used to search for randomized clinical trials. The occurrence of all strokes, of disabling strokes specifically, transient ischemic attacks (TIAs), all-cause mortality, and vascular complications were analyzed. Conventional meta-analysis was conducted using fixed-effects modeling and trial sequential analysis (TSA: type I error of 5%, power of 90%). The systematic review protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO; CRD420251081075). Results: In total, eight clinical trials were included, gathering 11,589 patients randomized between those who used the devices (5,943) and those who did not (5,646). The meta-analysis demonstrated no significant association between CEP use and reduced odds of all-cause stroke (OR = 0.92, 95% CI: 0.73–1.15, p = 0.46) and disabling stroke (OR = 0.80, 95% CI: 0.57–1.13, p = 0.20). The sequential analysis identified a lack of evidence for all strokes (required sample size [rSS] = 38,626; 10.53%), disabling strokes (rSS = 59,732; 17.05%). In terms of mortality, there was no significance in the use of devices (OR = 1.09, 95% CI: 0.71–1.69, p = 0.69), reaching evidence for support (rSS = 7,053; 42.25%); Conclusion: The data on the use of CEP is insufficient to support meta-analytic conclusions regarding cerebrovascular outcomes. Nevertheless, TSA demonstrated evidence supporting futility regarding mortality reduction.
SN - 0004-282X
SN - 1678-4227
ER -